



## Press release

Milan, September 10<sup>th</sup>, 2025

### Milan to Host the Joint International Conference 2025 on New Drugs and the Impact of AI in Oncology.

**Fondazione Gianni Bonadonna** with the **Prada Group** as supporting partner, **Fondazione Michelangelo Onlus** and the **European School of Oncology**, are pleased to announce that on **12–13 November 2025**, Milan will host the “**Joint International Conference 2025: Innovation in Oncology: New Drugs and the Impact of Artificial Intelligence**”. The event will take place at Fondazione Prada’s Milan venue.

The two-day meeting will bring together world-leading experts in oncology to discuss the **latest frontiers in drug development, diagnostics innovation, and new therapeutic opportunities**. Special focus will be given to the **transformative role of artificial intelligence in cancer care**.

*“This Conference offers a unique opportunity to connect diverse fields of research, from novel drug development to artificial intelligence. By fostering scientific dialogue and collaboration, we aim to inspire new ideas that can shape the future of oncology. It is also an extraordinary occasion for young researchers to learn from world-leading experts and engage directly with them”* – underline **Carmen Criscitiello and Giampaolo Bianchini**, Scientific Secretariat of the Event.

*“Training the next generation of oncologists and promoting multidisciplinary approaches to cancer care are among ESO’s core priorities. We are therefore honoured to contribute to this Conference, which offers a valuable platform for the exchange of knowledge and innovation in oncology”* – affirms **Alberto Costa**, CEO of the European School of Oncology.



The Conference will host the **“Gianni Bonadonna Prize 2025” Ceremony**. Fondazione Gianni Bonadonna will award a promising young researcher who has demonstrated exceptional originality, research independence, and clinical impact in oncology. The awardee will be selected from nominees put forward by an outstanding panel of international experts.

This year’s edition also marks the **10<sup>th</sup> anniversary of Gianni Bonadonna’s passing**, honoring the legacy of a pioneer who revolutionized cancer treatment worldwide.

*“Gianni Bonadonna was an outstanding medical researcher who introduced and applied the science of clinical trials to oncology, making key advances in cancer therapy that changed patients’ lives. He valued the energy and scientific entrepreneurship of young collaborators and was eager to explore preclinical studies for inspiration in designing new clinical trials. The Gianni Bonadonna Prize aims to recognize the same spirit of innovation in today’s young investigators”* – says **Luca Gianni**, President of Fondazione Gianni Bonadonna.

For further information and registration: <https://bit.ly/innovationoncology>

**Fondazione Gianni Bonadonna** – Fondazione Gianni Bonadonna was launched to honor and pursue the legacy of Gianni Bonadonna, founding father of modern oncology who developed key new therapies for women with breast cancer and patients with lymphomas. Fondazione Gianni Bonadonna's mission is to promote therapeutic innovation from the earliest phases of research and support the education of new generations of physician-scientists in oncology.

**Fondazione Michelangelo Onlus** – Fondazione Michelangelo Onlus is a non-profit scientific, independent organization aiming at the progress in cancer research and treatment development.

Founded in December 1999 by Gianni Bonadonna, the Foundation's aim is fostering progress in cancer research and improving anticancer treatment options, through the promotion and of conduction clinical and translational research projects in oncology.

**Prada Group** – The Prada Group is socially engaged to contribute to the sustainable development of the communities and stimulate the cultural debate in all its forms of expression. The Group partners with recognized players and international entities to develop educational and training programs, value talent, support scientific research, foster women's empowerment, and promote local culture and artistic heritage. The Prada Group operates in the luxury sector through the Prada, Miu Miu, Church's, Car Shoe, Marchesi 1824 and Luna Rossa brands.

**European School of Oncology** – The European School of Oncology (ESO) is an independent and self-funded non-profit organization, dedicated to high-quality education and training in oncology, to provide patients with equal access to the standard of care. ESO was founded in 1982 by Umberto Veronesi and Laudomia Del Drago, with the mission to reduce the number of cancer deaths due to late diagnosis or inadequate treatment. With the same commitment, ESO today provides extensive and multidisciplinary oncology education programs for the improvement of treatment options for cancer patients.